Recently, some studies have discovered that kindlin-2 mutation or dysregulation can promote the development of certain cancers, including breast cancer, hepatocellular carcinoma (HCC), esophageal cancer, prostate cancer, gastric cancer and glioma progression [19–25]. Here, FERMT2 is linked to gastric cancer.